Close Menu

quantum dots

The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.

NEW YORK (GenomeWeb News) – Quantum Materials and NanoAxis have forged a deal combining their technologies for diagnostic and pharmaceutical applications.

Quantum Materials and Nanoaxis this week announced a partnership that will see the firms pair their respective technologies to develop microarray-based tests for a variety of conditions.

Building on its experience in different technology areas, the company is currently developing the single-molecule platform, which it plans to start testing next year with external collaborators such as the J. Craig Venter Institute.

Short Reads: Mar 24, 2009

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Life Technologies is looking to expand uses of its quantum dot technology beyond life sciences and into applied fields, such as counterfeit detection.

Proteins, Front and Center

Premium

Once a tool that only piqued the interest of technology developers, protein microarrays have come into their own as scientists find new ways to apply them in basic and translational studies.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.